Secret Survey Roots Out Korean Firms Offering Rebates
This article was originally published in PharmAsia News
Executive Summary
In an unprecedented move to eliminate rebates in the pharma industry, South Korean pharma firms have conducted an anonymous survey to identify firms suspected of being involved in the practice in return for prescriptions.
You may also be interested in...
Novartis Korea May Face Business Suspension In Rebate Probe
Novartis’ South Korean subsidiary could face a business suspension and other administrative measures after prosecutors indicted several employees without detention on charges of illegal rebate payments.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.